Shanghai Laishi (002252.SZ) subsidiary obtained human fibrinogen drug registration certificate

According to Zhitong Finance App, Shanghai Laishi (002252.SZ) announced that Nanyue Biopharmaceutical Co., Ltd. (“Nanyue Biopharmaceutical”), a wholly-owned subsidiary of the company, recently received a “Drug Registration Certificate” for human fibrinogen issued by the State Drug Administration. Human fibrinogen is produced from healthy human plasma through separation, purification, and virus removal, inactivation treatment, and freeze-drying. This product from Nanyue Biotech is used for congenital fibrinogen reduction or deficiency.